Literature DB >> 22770243

Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.

Kiichiro Tomoda1, Kazutoshi Takahashi, Karen Leung, Aki Okada, Megumi Narita, N Alice Yamada, Kirsten E Eilertson, Peter Tsang, Shiro Baba, Mark P White, Salma Sami, Deepak Srivastava, Bruce R Conklin, Barbara Panning, Shinya Yamanaka.   

Abstract

Female human induced pluripotent stem cell (hiPSC) lines exhibit variability in X-inactivation status. The majority of hiPSC lines maintain one transcriptionally active X (Xa) and one inactive X (Xi) chromosome from donor cells. However, at low frequency, hiPSC lines with two Xas are produced, suggesting that epigenetic alterations of the Xi occur sporadically during reprogramming. We show here that X-inactivation status in female hiPSC lines depends on derivation conditions. hiPSC lines generated by the Kyoto method (retroviral or episomal reprogramming), which uses leukemia inhibitory factor (LIF)-expressing SNL feeders, frequently had two Xas. Early passage Xa/Xi hiPSC lines generated on non-SNL feeders were converted into Xa/Xa hiPSC lines after several passages on SNL feeders, and supplementation with recombinant LIF caused reactivation of some of X-linked genes. Thus, feeders are a significant factor affecting X-inactivation status. The efficient production of Xa/Xa hiPSC lines provides unprecedented opportunities to understand human X-reactivation and -inactivation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22770243      PMCID: PMC3396435          DOI: 10.1016/j.stem.2012.05.019

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  33 in total

1.  Female human iPSCs retain an inactive X chromosome.

Authors:  Jason Tchieu; Edward Kuoy; Mark H Chin; Hung Trinh; Michaela Patterson; Sean P Sherman; Otaren Aimiuwu; Anne Lindgren; Shahrad Hakimian; Jerome A Zack; Amander T Clark; April D Pyle; William E Lowry; Kathrin Plath
Journal:  Cell Stem Cell       Date:  2010-08-19       Impact factor: 24.633

2.  Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells.

Authors:  Jose M Polo; Susanna Liu; Maria Eugenia Figueroa; Warakorn Kulalert; Sarah Eminli; Kah Yong Tan; Effie Apostolou; Matthias Stadtfeld; Yushan Li; Toshi Shioda; Sridaran Natesan; Amy J Wagers; Ari Melnick; Todd Evans; Konrad Hochedlinger
Journal:  Nat Biotechnol       Date:  2010-07-19       Impact factor: 54.908

Review 3.  Naive and primed pluripotent states.

Authors:  Jennifer Nichols; Austin Smith
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

4.  Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations.

Authors:  Christopher J Lengner; Alexander A Gimelbrant; Jennifer A Erwin; Albert Wu Cheng; Matthew G Guenther; G Grant Welstead; Raaji Alagappan; Garrett M Frampton; Ping Xu; Julien Muffat; Sandro Santagata; Doug Powers; C Brent Barrett; Richard A Young; Jeannie T Lee; Rudolf Jaenisch; Maisam Mitalipova
Journal:  Cell       Date:  2010-05-13       Impact factor: 41.582

5.  Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.

Authors:  Nimet Maherali; Rupa Sridharan; Wei Xie; Jochen Utikal; Sarah Eminli; Katrin Arnold; Matthias Stadtfeld; Robin Yachechko; Jason Tchieu; Rudolf Jaenisch; Kathrin Plath; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

6.  Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs.

Authors:  Jacob Hanna; Albert W Cheng; Krishanu Saha; Jongpil Kim; Christopher J Lengner; Frank Soldner; John P Cassady; Julien Muffat; Bryce W Carey; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-04       Impact factor: 11.205

7.  Induction of pluripotency in human endothelial cells resets epigenetic profile on genome scale.

Authors:  Maria A Lagarkova; Maria V Shutova; Alexandra N Bogomazova; Ekaterina M Vassina; Evgeny A Glazov; Ping Zhang; Albert A Rizvanov; Ilya V Chestkov; Sergey L Kiselev
Journal:  Cell Cycle       Date:  2010-03-06       Impact factor: 4.534

8.  Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells.

Authors:  Carol B Ware; Linlin Wang; Brigham H Mecham; Lanlan Shen; Angelique M Nelson; Merav Bar; Deepak A Lamba; Derek S Dauphin; Brian Buckingham; Bardia Askari; Raymond Lim; Muneesh Tewari; Stanley M Gartler; Jean-Pierre Issa; Paul Pavlidis; Zhijun Duan; C Anthony Blau
Journal:  Cell Stem Cell       Date:  2009-04-03       Impact factor: 24.633

9.  X chromosome inactivation is initiated in human preimplantation embryos.

Authors:  Ilse M van den Berg; Joop S E Laven; Mary Stevens; Iris Jonkers; Robert-Jan Galjaard; Joost Gribnau; J Hikke van Doorninck
Journal:  Am J Hum Genet       Date:  2009-05-28       Impact factor: 11.025

10.  Human induced pluripotent stem cells on autologous feeders.

Authors:  Kazutoshi Takahashi; Megumi Narita; Midori Yokura; Tomoko Ichisaka; Shinya Yamanaka
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more
  54 in total

1.  Isolation and cultivation of naive-like human pluripotent stem cells based on HERVH expression.

Authors:  Jichang Wang; Manvendra Singh; Chuanbo Sun; Daniel Besser; Alessandro Prigione; Zoltán Ivics; Laurence D Hurst; Zsuzsanna Izsvák
Journal:  Nat Protoc       Date:  2016-01-21       Impact factor: 13.491

Review 2.  Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies.

Authors:  Xixi Du; Jack M Parent
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 3.  Chromatin changes in reprogramming of mammalian somatic cells.

Authors:  Rong Xu; Shiqiang Zhang; Anmin Lei
Journal:  Rejuvenation Res       Date:  2014-02       Impact factor: 4.663

4.  Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.

Authors:  Michiyo Koyanagi-Aoi; Mari Ohnuki; Kazutoshi Takahashi; Keisuke Okita; Hisashi Noma; Yuka Sawamura; Ito Teramoto; Megumi Narita; Yoshiko Sato; Tomoko Ichisaka; Naoki Amano; Akira Watanabe; Asuka Morizane; Yasuhiro Yamada; Tosiya Sato; Jun Takahashi; Shinya Yamanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-20       Impact factor: 11.205

5.  Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation.

Authors:  Chun-Ting Lee; Raphael M Bendriem; Abigail A Kindberg; Lila T Worden; Melanie P Williams; Tomas Drgon; Barbara S Mallon; Brandon K Harvey; Christopher T Richie; Rebecca S Hamilton; Jia Chen; Stacie L Errico; Shang-Yi A Tsai; George R Uhl; William J Freed
Journal:  Cell Rep       Date:  2015-01-29       Impact factor: 9.423

6.  Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2).

Authors:  Yoshiaki Tanaka; Kun-Yong Kim; Mei Zhong; Xinghua Pan; Sherman Morton Weissman; In-Hyun Park
Journal:  Hum Mol Genet       Date:  2013-10-15       Impact factor: 6.150

7.  Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program.

Authors:  Cody Kime; Masayo Sakaki-Yumoto; Leeanne Goodrich; Yohei Hayashi; Salma Sami; Rik Derynck; Michio Asahi; Barbara Panning; Shinya Yamanaka; Kiichiro Tomoda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-13       Impact factor: 11.205

8.  Coupling of X-chromosome reactivation with the pluripotent stem cell state.

Authors:  Bernhard Payer; Jeannie T Lee
Journal:  RNA Biol       Date:  2014-08-19       Impact factor: 4.652

Review 9.  Epigenetics of reprogramming to induced pluripotency.

Authors:  Bernadett Papp; Kathrin Plath
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

Review 10.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.